NOVO NORDISK A/S-B (NOV.DE) Stock Price, Forecast & Analysis
Europe - FRA:NOV - DK0062498333 - Common Stock
NOV.DE Key Statistics, Chart & Performance
The current stock price of NOV.DE is 42.855 EUR. In the past month the price decreased by -12.39%. In the past year, price decreased by -56.06%.
NOV.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 11.72 | 217.05B | ||
| SAN.PA | SANOFI | 11.86 | 219.55B | ||
| MRK.DE | MERCK KGAA | 13.6 | 50.30B | ||
| UCB.BR | UCB SA | 35.75 | 44.64B | ||
| BAYN.DE | BAYER AG-REG | 5.8 | 28.55B | ||
| 1BAYN.MI | BAYER AG-REG | 5.41 | 26.60B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 27.13 | 11.18B | ||
| IPN.PA | IPSEN | 12.59 | 10.84B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 97.36 | 9.01B | ||
| VIRP.PA | VIRBAC SA | 20.62 | 3.00B | ||
| DMP.DE | DERMAPHARM HOLDING SE | 17.12 | 1.83B | ||
| MEDCL.PA | MEDINCELL SA | N/A | 1.02B |
Related stock screener links
About NOV.DE
Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company Info
NOVO NORDISK A/S-B
Novo Alle 1
Bagsvaerd DK
Employees: 78387
Phone: 4544448888
NOVO NORDISK A/S-B / NOV.DE FAQ
What does NOV do?
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
What is the current price of NOV stock?
The current stock price of NOV.DE is 42.855 EUR. The price increased by 1.05% in the last trading session.
Does NOV stock pay dividends?
NOVO NORDISK A/S-B (NOV.DE) has a dividend yield of 3.8%. The yearly dividend amount is currently 1.33.
What is the ChartMill technical and fundamental rating of NOV stock?
NOV.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the analyst forecast for NOV.DE stock?
31 analysts have analysed NOV.DE and the average price target is 61.27 EUR. This implies a price increase of 42.97% is expected in the next year compared to the current price of 42.855.
What is the market capitalization of NOV stock?
NOVO NORDISK A/S-B (NOV.DE) has a market capitalization of 190.43B EUR. This makes NOV.DE a Large Cap stock.
NOV.DE Technical Analysis
NOV.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NOV.DE. NOV.DE has an excellent profitability rating, but there are some minor concerns on its financial health.
NOV.DE Financial Highlights
Over the last trailing twelve months NOV.DE reported a non-GAAP Earnings per Share(EPS) of 3.41. The EPS increased by 20.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.88% | ||
| ROA | 20.26% | ||
| ROE | 61.08% | ||
| Debt/Equity | 0.52 |
NOV.DE Forecast & Estimates
31 analysts have analysed NOV.DE and the average price target is 61.27 EUR. This implies a price increase of 42.97% is expected in the next year compared to the current price of 42.855.
For the next year, analysts expect an EPS growth of 5.73% and a revenue growth 9.95% for NOV.DE